Dose-Limiting Toxicity

Dose-limiting toxicity defines the maximum tolerated dose in clinical trials representing the highest dose level producing manageable adverse effects without unacceptable safety detriment. Grade 3 or higher adverse events per Common Terminology Criteria for Adverse Events frequently define dose-limiting toxicity thresholds. Clinical trial designs employ dose escalation schemes identifying dose-limiting toxicity levels. Pharmaceutical potency and mechanism of action directly influence dose-limiting toxicity characteristics.

Immunomodulatory drugs frequently cause immune-related adverse events including colitis and hepatitis representing dose-limiting toxicities. Chemotherapy agents exhibit myelosuppression as typical dose-limiting toxicity. Target-specific toxicities reflect mechanism-of-action related effects. Patient population characteristics including age, renal function, and comorbidities influence dose-limiting toxicity severity. Biomarker-directed dose adjustment may enable tolerable dosing in susceptible subpopulations. Post-approval experience frequently identifies previously unrecognised dose-limiting toxicities warranting label modifications.